Centiva Capital LP Purchases 5,776 Shares of DaVita Inc. (NYSE:DVA)

Centiva Capital LP boosted its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 61.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,207 shares of the company's stock after purchasing an additional 5,776 shares during the quarter. Centiva Capital LP's holdings in DaVita were worth $2,493,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of DaVita by 1.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,759 shares of the company's stock worth $776,000 after buying an additional 70 shares during the period. Wedmont Private Capital boosted its position in DaVita by 4.4% during the 3rd quarter. Wedmont Private Capital now owns 1,776 shares of the company's stock worth $280,000 after acquiring an additional 75 shares during the period. Blue Trust Inc. grew its stake in shares of DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company's stock worth $29,000 after purchasing an additional 78 shares in the last quarter. First Trust Direct Indexing L.P. increased its holdings in shares of DaVita by 2.9% during the third quarter. First Trust Direct Indexing L.P. now owns 3,051 shares of the company's stock valued at $500,000 after purchasing an additional 86 shares during the period. Finally, Nisa Investment Advisors LLC raised its stake in shares of DaVita by 0.3% during the third quarter. Nisa Investment Advisors LLC now owns 36,820 shares of the company's stock valued at $6,036,000 after purchasing an additional 126 shares in the last quarter. Institutional investors own 90.12% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on DVA. Barclays upped their price target on shares of DaVita from $150.00 to $164.00 and gave the stock an "equal weight" rating in a research note on Thursday, October 31st. Truist Financial increased their price target on DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research note on Monday, October 7th. UBS Group boosted their price objective on DaVita from $169.00 to $175.00 and gave the stock a "buy" rating in a research note on Thursday, August 8th. Finally, Bank of America raised their target price on DaVita from $139.00 to $145.00 and gave the company an "underperform" rating in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $161.80.

Insider Buying and Selling

In related news, CEO Javier Rodriguez sold 50,000 shares of the business's stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the transaction, the chief executive officer now owns 837,835 shares in the company, valued at $138,284,666.75. The trade was a 5.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 2.00% of the stock is owned by corporate insiders.

DaVita Stock Up 0.4 %

DVA traded up $0.59 during trading on Tuesday, reaching $164.33. 255,014 shares of the stock traded hands, compared to its average volume of 818,004. The stock has a market cap of $13.48 billion, a price-to-earnings ratio of 17.71, a price-to-earnings-growth ratio of 0.94 and a beta of 0.90. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. DaVita Inc. has a fifty-two week low of $103.40 and a fifty-two week high of $169.51. The stock's 50-day simple moving average is $158.62 and its two-hundred day simple moving average is $149.67.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). The business had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. DaVita's revenue was up 4.6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.85 earnings per share. As a group, equities research analysts expect that DaVita Inc. will post 9.71 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.